Chris Sampson is Senior Principal Economist at the Office of Health Economics. He researches methodological and policy challenges in valuing health interventions. He leads research commissioned by the Cell and Gene Therapy Catapult on the value of cell and gene therapies to the UK economy. Broader interests include cost-effectiveness thresholds, health state valuation, and climate impacts in healthcare. He is Honorary Associate Professor at the University of Nottingham and a member of the EuroQol Group.